Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 10 mg/ml - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; water for injections - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 300 mg/ml - eq. magnesium 29,58 mg/ml - concentrate for solution for infusion - 300 mg/ml - magnesium sulfate heptahydrate 300 mg/ml - magnesium sulfate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 300 mg/ml - eq. magnesium 29,58 mg/ml - concentrate for solution for infusion - 300 mg/ml - magnesium sulfate heptahydrate 300 mg/ml - magnesium sulfate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 500 mg/ml - eq. magnesium 49,35 mg/ml - concentrate for solution for infusion - 500 mg/ml - magnesium sulfate heptahydrate 500 mg/ml - magnesium sulfate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 2 g/10 ml - concentrate for solution for infusion - 2 g/10 ml - magnesium sulfate heptahydrate 200 mg/ml - magnesium sulfate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 500 mg/ml - eq. magnesium 49,35 mg/ml - concentrate for solution for infusion - 500 mg/ml - magnesium sulfate heptahydrate 500 mg/ml - magnesium sulfate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 300 mg/ml - eq. magnesium 29,58 mg/ml - concentrate for solution for infusion - 300 mg/ml - magnesium sulfate heptahydrate 300 mg/ml - magnesium sulfate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 100 mg/ml - eq. magnesium 9,87 mg/ml - solution for injection - 1 g/10 ml - magnesium sulfate heptahydrate 100 mg/ml - magnesium sulfate

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - suxamethonium chloride dihydrate, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid - for the production of skeletal muscle relaxation in anaesthesia. suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.